Get the Stockscreener App
11.47
0.95%
-0.11
After Hours:
11.60
0.13
+1.13%
Replimune Group Inc stock is traded at $11.47, with a volume of 1.63M.
It is down -0.95% in the last 24 hours and up +21.12% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
See More
Previous Close:
$11.58
Open:
$11.53
24h Volume:
1.63M
Relative Volume:
0.22
Market Cap:
$962.85M
Revenue:
-
Net Income/Loss:
$-314.85M
P/E Ratio:
-3.2017
EPS:
-3.5825
Net Cash Flow:
$-283.27M
1W Performance:
+2.41%
1M Performance:
+21.12%
6M Performance:
+35.74%
1Y Performance:
+22.02%
1-Day Range:
$11.33
$11.75
1-Week Range:
$10.97
$12.50
52-Week Range:
$1.50
$13.24
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
11.47 | 929.27M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| Apr-13-26 | Downgrade | H.C. Wainwright | Buy → Sell |
| Apr-13-26 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-13-26 | Downgrade | Jefferies | Buy → Hold |
| Apr-13-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-13-26 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-10-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-03-25 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| Oct-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-20-25 | Upgrade | Wedbush | Neutral → Outperform |
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
REPL Maintains Neutral Rating by Wedbush -- Price Target Raised to $9.00 - GuruFocus
Replimune: Stock Buoyant On Third Try At RP1 ApprovalFDA AdCom May Be Crucial (REPL) - Seeking Alpha
REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug - Stocktwits
BMO Capital Upgrades Replimune to Outperform From Underperform, Adjusts PT to $16 From $1 - marketscreener.com
BMO upgrades Replimune stock rating on FDA filing progress By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Replimune Group, Inc. Stock 12‑Month Price Target Raised to $8.17, Implies 30% Downside - TradingView
Replimune's Fiscal Q4 Net Loss Narrows - Moomoo
Replimune gets FDA review for melanoma drug after prior setbacks - The Pharma Letter
Replimune Group Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Replimune Group FY 2026: Revenue $0 Net loss $(313.9)M — 10-K Summary - TradingView
Replimune (NASDAQ: REPL) outlines RP1 melanoma data and high-stakes FDA review - Stock Titan
Replimune Group reports FY2026 net loss $313.9M, cash $268.9M, FDA accepts RP1 BLA resubmission - TradingView
Replimune (REPL) widens FY 2026 loss as FDA accepts RP1 melanoma BLA - Stock Titan
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update - The Manila Times
Press Release: Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update - Moomoo
Replimune reports fiscal 2026 results and FDA BLA progress for RP1 in melanoma - grafa.com
Investors SueWallSt as Replimune Group, Inc. Faces Securities Fraud Allegations - The National Law Review
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - The National Law Review
Replimune upgraded by Analyst with a new price target - Quantisnow
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
Replimune (REPL) Receives Upgrade from JPMorgan with Increased P - GuruFocus
Replimune (REPL) Receives FDA Review for Advanced Melanoma Treat - GuruFocus
Replimune Group, Inc. Stock 12‑Month Price Target Raised to $7.67, Implies 31% Downside - TradingView
Replimune reveals FDA acceptance of resubmitted BLA for RP1 plus nivolumab - grafa.com
FDA accepts Replimune’s resubmitted application for RP1 - Investing.com UK
Replimune Group Inc : JP Morgan Raises to Ove - Moomoo
JPMorgan Upgrades Replimune Group to Overweight From Neutral, $17 Price Target - marketscreener.com
FDA accepts Replimune’s resubmitted application for RP1 By Investing.com - Investing.com Australia
JPMorgan released its latest research report, significantly upgrading the stock rating of biotechnology company Replimune Group Inc. from "Neutral" to "Overweight." - Bitget
Replimune Group Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1 for the treatment of advanced melanoma. - Bitget
Replimune (REPL) Shares Decline After FDA Advisory Committee Ann - GuruFocus
Replimune Group Stock Short Interest Falls to 54.56% - Quiver Quantitative
Replimune’s RP1 Melanoma Therapy BLA Resubmission Accepted by FDA; Decision Expected August 2026 - Minichart
Enterprise value to EBITDA forward of Replimune Group, Inc. – NASDAQ:REPL - TradingView
Replimune Says FDA Accepts Melanoma Drug Resubmission, Sets Aug. 2 Target Action Date - marketscreener.com
Replimune’s RP1 BLA Resubmission Accepted for Review - TipRanks
Replimune: FDA Accepts RP1 BLA Resubmission with Aug. 2, 2026 Goal Date - TradingView
Replimune to face AdCom panel as lead drug accepted for FDA review - Seeking Alpha
[8-K] Replimune Group, Inc. Reports Material Event - Stock Titan
Replimune Group Announces FDA Acceptance for Review of RP1 BLA Resubmission in Advanced Melanoma - Quiver Quantitative
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma - The Manila Times
FDA accepts Replimune’s melanoma drug review, decision due Aug. 2 - Stock Titan
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services - Yahoo Finance
REPL Forecast — Price Target — Prediction for 2027 - TradingView
Replimune Group, Inc. Actuals & Estimates (SWB:7R8) - TradingView
Replimune Group, Inc. Actuals & Estimates (MUN:7R8) - TradingView
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Replimune Group Inc Stock (REPL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Xynos Konstantinos | Chief Medical Officer |
May 18 '26 |
Sale |
5.08 |
14,023 |
71,237 |
235,662 |
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
| Hill Emily Luisa | Chief Financial Officer |
May 18 '26 |
Sale |
5.08 |
7,812 |
39,685 |
236,556 |
| Sarchi Christopher | Chief Commercial Officer |
Apr 02 '26 |
Sale |
8.01 |
6,500 |
52,065 |
151,588 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):